An Optically Pure Apogossypolone Derivative As Potent Pan-active Inhibitor of Anti-apoptotic Bcl-2 Family Proteins

Overview

Journal Front Oncol

Specialty Oncology

Date 2012 Jun 2

PMID 22655238

Citations 22

Authors

Jun Wei

John L Stebbins

Shinichi Kitada

Rupesh Dash

Dayong Zhai

William J Placzek

Bainan Wu

Michele F Rega

Ziming Zhang

Elisa Barile

Li Yang

Russell Dahl

Paul B Fisher

John C Reed

Maurizio Pellecchia

Affiliations

Soon will be listed here.

Abstract

Our focus in the past several years has been on the identification of novel and effective pan-Bcl-2 antagonists. We have recently reported a series of Apogossypolone (ApoG2) derivatives, resulting in the chiral compound (±) BI97D6. We report here the synthesis and evaluation on its optically pure (-) and (+) atropisomers. Compound (-) BI97D6 potently inhibits the binding of BH3 peptides to Bcl-X(L), Bcl-2, Mcl-1, and Bfl-1 with IC(50) values of 76 ± 5, 31 ± 2, 25 ± 8, and 122 ± 28 nM, respectively. In a cellular assay, compound (-) BI97D6 effectively inhibits cell growth in the PC-3 human prostate cancer and H23 human lung cancer cell lines with EC(50) values of 0.22 ± 0.08 and 0.14 ± 0.02 μM, respectively. Similarly, compound (-) BI97D6 effectively induces apoptosis in the BP3 human lymphoma cell line in a dose-dependent manner. The compound also shows little cytotoxicity against bax(-/-)/bak(-/-) cells, suggesting that it kills cancers cells predominantly via a Bcl-2 pathway. Moreover, compound (-) BI97D6 displays in vivo efficacy in both a Bcl-2-transgenic mouse model and in a prostate cancer xenograft model in mice. Therefore, compound (-) BI97D6 represents a promising drug lead for the development of novel apoptosis-based therapies for cancer.

Citing Articles

Hypericin, a potential new BH3 mimetic.

Doroshenko A, Tomkova S, Kozar T, Stroffekova K Front Pharmacol. 2022; 13:991554.

PMID: 36267274 PMC: 9577225. DOI: 10.3389/fphar.2022.991554.

Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.

Westaby D, Jimenez-Vacas J, Padilha A, Varkaris A, Balk S, de Bono J Cancers (Basel). 2022; 14(1).

PMID: 35008216 PMC: 8750516. DOI: 10.3390/cancers14010051.

Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1.

Gambini L, Udompholkul P, Baggio C, Muralidharan A, Kenjic N, Assar Z J Med Chem. 2021; 64(8):4903-4912.

PMID: 33797903 PMC: 8550878. DOI: 10.1021/acs.jmedchem.1c00005.

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening.

Mady A, Liao C, Bajwa N, Kump K, Abulwerdi F, Lev K Sci Rep. 2018; 8(1):10210.

PMID: 29976942 PMC: 6033896. DOI: 10.1038/s41598-018-27899-9.

Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway.

Pradhan A, Bhoopathi P, Talukdar S, Shen X, Emdad L, Das S Mol Cancer Ther. 2018; 17(9):1951-1960.

PMID: 29934341 PMC: 7598934. DOI: 10.1158/1535-7163.MCT-17-1002.

References

Reed J . Bcl-2 family proteins. Oncogene. 1999; 17(25):3225-36. DOI: 10.1038/sj.onc.1202591. View

Placzek W, Wei J, Kitada S, Zhai D, Reed J, Pellecchia M . A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2011; 1:e40. PMC: 3032312. DOI: 10.1038/cddis.2010.18. View

Katsumata M, Siegel R, Louie D, Miyashita T, Tsujimoto Y, Nowell P . Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A. 1992; 89(23):11376-80. PMC: 50553. DOI: 10.1073/pnas.89.23.11376. View

Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zhai D . Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004; 11(3):389-95. DOI: 10.1016/j.chembiol.2004.02.020. View

Wei J, Stebbins J, Kitada S, Dash R, Placzek W, Rega M . BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 2010; 53(10):4166-76. PMC: 2880850. DOI: 10.1021/jm1001265. View

Sun J, Li Z, Hu Z, Zeng Z, Yang D, Jiang W . Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells. Oncol Rep. 2009; 22(1):193-8. DOI: 10.3892/or_00000424. View

Mohammad R, Wang S, Aboukameel A, Chen B, Wu X, Chen J . Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther. 2005; 4(1):13-21. View

Teschner M, Henn C, Vollhardt H, Reiling S, Brickmann J . Texture mapping: a new tool for molecular graphics. J Mol Graph. 1994; 12(2):98-105. DOI: 10.1016/0263-7855(94)80074-x. View

Muchmore S, Sattler M, Liang H, Meadows R, Harlan J, Yoon H . X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature. 1996; 381(6580):335-41. DOI: 10.1038/381335a0. View

10.

Dash R, Azab B, Quinn B, Shen X, Wang X, Das S . Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A. 2011; 108(21):8785-90. PMC: 3102401. DOI: 10.1073/pnas.1100769108. View

11.

Ramjaun A, Tomlinson S, Eddaoudi A, Downward J . Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis. Oncogene. 2006; 26(7):970-81. DOI: 10.1038/sj.onc.1209852. View

12.

Wang G, Nikolovska-Coleska Z, Yang C, Wang R, Tang G, Guo J . Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006; 49(21):6139-42. DOI: 10.1021/jm060460o. View

13.

Wesarg E, Hoffarth S, Wiewrodt R, Kroll M, Biesterfeld S, Huber C . Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 2007; 121(11):2387-94. DOI: 10.1002/ijc.22977. View

14.

Reed J . Apoptosis-based therapies. Nat Rev Drug Discov. 2002; 1(2):111-21. DOI: 10.1038/nrd726. View

15.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

16.

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

17.

Lin J, Wu Y, Yang D, Zhao Y . [Effect of apogossypolone on induction apoptosis in multiple myeloma cells and its mechanisms]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009; 17(1):92-8. View

18.

Voortman J, Checinska A, Giaccone G, Rodriguez J, Kruyt F . Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther. 2007; 6(3):1046-53. DOI: 10.1158/1535-7163.MCT-06-0577. View

19.

Wei M, Zong W, Cheng E, LINDSTEN T, Panoutsakopoulou V, Ross A . Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517):727-30. PMC: 3049805. DOI: 10.1126/science.1059108. View

20.

Wei J, Kitada S, Rega M, Emdadi A, Yuan H, Cellitti J . Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009; 8(4):904-13. PMC: 2750823. DOI: 10.1158/1535-7163.MCT-08-1050. View